![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 62, Issue 3, 578-589, September 2002
Institut de Recherches Servier, Psychopharmacology Department,
chemin de Ronde, Croissy/Seine, Paris, France
As determined by a guanosine
5'-O-(3-[35S]thio)triphosphate
([35S]GTP
S) binding assay, which does not
distinguish G protein subtypes, 5-hydroxytryptamine (5-HT) and
2(S)- 1-(6-chloro-5-fluoro-1H-indol-1-yl)-2-propanamine fumarate (Ro600175) behaved as full agonists at human
5-HT2C (h5-HT2C) receptors (VSV isoform) stably
expressed in Chinese hamster ovary (CHO) cells, whereas
1-2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI),
d-lysergic acid diethylamide (LSD), and lisuride
exhibited partial agonist properties. After treatment with pertussis
toxin to uncouple 5-HT2C receptors from Gi/Go but not
Gq/11, DOI and LSD were as efficacious as 5-HT and Ro600175 in
stimulating [35S]GTPS binding, whereas lisuride still
exhibited low efficacy (40%). Correspondingly, in a scintillation
proximity assay employing specific antibodies against Gq/11, 5-HT,
Ro600175, DOI, and LSD behaved as high-efficacy agonists, whereas
lisuride showed efficacy of 36%. In contrast, when employing a
specific antibody recognizing Gi3, DOI and LSD were less
efficacious (80 and 30%, respectively) than 5-HT and Ro600175, and
lisuride was inactive. Agonist actions were specifically mediated by
h5-HT2C receptors inasmuch as the selective
5-HT2C antagonist SB242,084 blocked
[35S]GTPS binding at both Gq/11 and Gi3.
Agonist potency for stimulation of Gi3 was ~6- to 8-fold
less than for Gq/11, indicating that the latter was preferentially
engaged by h5-HT2C receptors. Inactivation of
h5-HT2C receptors with the alkylating agent
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline did not
modify the efficacy of 5-HT, Ro600175, and DOI at Gq/11, whereas their
efficacies were substantially reduced at Gi3, indicating a
greater receptor reserve for the former. Finally, the preferential activation of Gq/11 versus Gi3 by DOI, LSD, and lisuride
was diminished in the presence of lower receptor number. In conclusion,
h5-HT2C receptors couple to both Gq/11 and Gi3
in CHO cells, and efficacy for G protein subtype activation is both
ligand- and receptor reserve-dependent.
This article has been cited by other articles:
|
|
 |
|
  M. J. Millan, C. M. la Cour, F. Novi, R. Maggio, V. Audinot, A. Newman-Tancredi, D. Cussac, V. Pasteau, J.-A. Boutin, T. Dubuffet, et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 587 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-L. Lu, M. Coetsee, C. D. White, and R. P. Millar Structural Determinants for Ligand-Receptor Conformational Selection in a Peptide G Protein-coupled Receptor J. Biol. Chem., June 15, 2007; 282(24): 17921 - 17929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Lane, B. Powney, A. Wise, S. Rees, and G. Milligan Protean Agonism at the Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for Activation of Go1 but an Antagonist/Inverse Agonist for Gi1,Gi2, and Gi3 Mol. Pharmacol., May 1, 2007; 71(5): 1349 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Martel, A.-M. Ormiere, N. Leduc, M.-B. Assie, D. Cussac, and A. Newman-Tancredi Native Rat Hippocampal 5-HT1A Receptors Show Constitutive Activity Mol. Pharmacol., March 1, 2007; 71(3): 638 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Urban, W. P. Clarke, M. von Zastrow, D. E. Nichols, B. Kobilka, H. Weinstein, J. A. Javitch, B. L. Roth, A. Christopoulos, P. M. Sexton, et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 1 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lavialle-Defaix, H. Gautier, A. Defaix, B. Lapied, and F. Grolleau Differential Regulation of Two Distinct Voltage-Dependent Sodium Currents by Group III Metabotropic Glutamate Receptor Activation in Insect Pacemaker Neurons J Neurophysiol, November 1, 2006; 96(5): 2437 - 2450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. la Cour, S. El Mestikawy, N. Hanoun, M. Hamon, and L. Lanfumey Regional Differences in the Coupling of 5-Hydroxytryptamine-1A Receptors to G Proteins in the Rat Brain Mol. Pharmacol., September 1, 2006; 70(3): 1013 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Andressen, J. H. Norum, F. O. Levy, and K. A. Krobert Activation of Adenylyl Cyclase by Endogenous Gs-Coupled Receptors in Human Embryonic Kidney 293 Cells Is Attenuated by 5-HT7 Receptor Expression Mol. Pharmacol., January 1, 2006; 69(1): 207 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Miller SEROTONIN 5-HT2C RECEPTOR AGONISTS: POTENTIAL FOR THE TREATMENT OF OBESITY Mol. Interv., October 1, 2005; 5(5): 282 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Turner and J. R. Raymond Interaction of Calmodulin with the Serotonin 5-Hydroxytryptamine2A Receptor: A PUTATIVE REGULATOR OF G PROTEIN COUPLING AND RECEPTOR PHOSPHORYLATION BY PROTEIN KINASE C J. Biol. Chem., September 2, 2005; 280(35): 30741 - 30750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Hazelwood and E. Sanders-Bush His452Tyr Polymorphism in the Human 5-HT2A Receptor Destabilizes the Signaling Conformation Mol. Pharmacol., November 1, 2004; 66(5): 1293 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. H. Moniri, D. Covington-Strachan, and R. G. Booth Ligand-Directed Functional Heterogeneity of Histamine H1 Receptors: Novel Dual-Function Ligands Selectively Activate and Block H1-Mediated Phospholipase C and Adenylyl Cyclase Signaling J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 274 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Millan, D. Cussac, A. Gobert, F. Lejeune, J.-M. Rivet, C. M. La Cour, A. Newman-Tancredi, and J.-L. Peglion S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 903 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Simons, S. M. Biggs, A. Waller, T. Foutz, D. F. Cimino, Q. Guo, R. R. Neubig, W.-J. Tang, E. R. Prossnitz, and L. A. Sklar Real-time Analysis of Ternary Complex on Particles: DIRECT EVIDENCE FOR PARTIAL AGONISM AT THE AGONIST-RECEPTOR-G PROTEIN COMPLEX ASSEMBLY STEP OF SIGNAL TRANSDUCTION J. Biol. Chem., April 2, 2004; 279(14): 13514 - 13521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gonzalez-Maeso, T. Yuen, B. J. Ebersole, E. Wurmbach, A. Lira, M. Zhou, N. Weisstaub, R. Hen, J. A. Gingrich, and S. C. Sealfon Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex J. Neurosci., October 1, 2003; 23(26): 8836 - 8843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Millan, A. Gobert, F. Lejeune, A. Dekeyne, A. Newman-Tancredi, V. Pasteau, J.-M. Rivet, and D. Cussac The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 954 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Skrzydelski, A.-M. Lhiaubet, A. Lebeau, P. Forgez, M. Yamada, E. Hermans, W. Rostene, and D. Pelaprat Differential Involvement of Intracellular Domains of the Rat NTS1 Neurotensin Receptor in Coupling to G Proteins: A Molecular Basis for Agonist-Directed Trafficking of Receptor Stimulus Mol. Pharmacol., August 1, 2003; 64(2): 421 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Newman-Tancredi, D. Cussac, Y. Quentric, M. Touzard, L. Verriele, N. Carpentier, and M. J. Millan Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 815 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Manning Measures of Efficacy Using G Proteins as Endpoints: Differential Engagement of G Proteins through Single Receptors Mol. Pharmacol., September 1, 2002; 62(3): 451 - 452. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
